Seminars in Hematology
Volume 45, Issue 1 , Pages 3-7 , January 2008

World Health Organization and International Prognostic Scoring System: The Limitations of Current Classification Systems in Assessing Prognosis and Determining Appropriate Therapy in Myelodysplastic Syndromes

  • Charles A. Schiffer

      Affiliations

    • Corresponding Author InformationAddress correspondence to Charles A. Schiffer, MD, Division of Hematology/Oncology, Karmanos Cancer Institute, HWCRB-4th Floor, 4100 John R, Wayne State University School of Medicine, Detroit, MI 48201.

References 

  1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  3. Haase D, Steidl C, Schanz J, Schabla R, Pfeilstöcker M, Nösslinger T, et al. Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS. Blood. 2005;106(suppl):787
  4. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol. 2006;23:7594–7603
  5. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223–2231
  6. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  7. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  8. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E. The WHO classification of MDS does make a difference. Blood. 2004;103:3265–3270
  9. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res. 2000;24:983–992
  10. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98:2935–2941
  11. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649
  12. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. A randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429–2440
  13. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  14. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  15. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  16. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Myelodysplastic Syndrome-003 Study Investigators (Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion). N Engl J Med. 2006;355:1456–1465
  17. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137:156–163
  18. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100:3639–3645
  19. Valent H, Horny J, Bennett C, Fonatsch U, Germing P, Greenberg T, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31:727–736

PII: S0037-1963(07)00153-9

doi: 10.1053/j.seminhematol.2007.10.002

Seminars in Hematology
Volume 45, Issue 1 , Pages 3-7 , January 2008

Article Tools